Over the decades, many hospitals were reimbursed or paid less than cost by federal and managed-care payers. These shortfalls were often subsidized through selective-price adjustments or cross-subsidization. After years of deploying such techniques, chargemaster pricing has become indefensible and hospital CFOs find themselves facing renewed, intense public price scrutiny — and with chargemasters that are difficult to explain to outside observers.